Ketoconazole Esteve (Ketoconazole)

Ketoconazole blocks the fungal cytochrome P450 14α‑demethylase enzyme, preventing conversion of lanosterol to ergosterol. This inhibition disrupts the fungal cell membrane, impairing growth and leading to cell death of susceptible yeasts and molds.

The dosage and duration of Ketoconazole Esteve are determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. No standardized dose is provided here.

Safety data for ketoconazole in pregnancy and lactation are limited. It is generally classified as contraindicated or to be used only when the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Ketoconazole belongs to the imidazole class, which differs from azoles like fluconazole or itraconazole in its broader spectrum against certain dermatophytes and systemic fungi, but it has a higher potential for liver toxicity and drug‑drug interactions. Choice of therapy depends on infection type, susceptibility patterns, and patient safety considerations.

Store the product at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Ketoconazole Esteve is taken orally, usually with a full glass of water. It should be administered with food to enhance absorption, unless the prescribing information advises otherwise.

Serious risks include hepatotoxicity (potentially severe liver injury), adrenal insufficiency due to inhibition of steroid synthesis, and cardiac arrhythmias such as QT prolongation. Patients should be monitored for signs of liver dysfunction, abnormal fatigue, dizziness, or palpitations.

Ketoconazole should be avoided in individuals with known hypersensitivity to ketoconazole or other imidazole antifungals, in patients with severe liver disease, and in those taking medications that have a high risk of dangerous interactions, such as certain statins, ergot derivatives, or medications that prolong the QT interval.